Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label EORTC. Show all posts
Showing posts with label EORTC. Show all posts
Friday, February 17, 2012

Still waiting for the world to catch up - Ignace Vergote - Cancer World - including comments on CA-125/biomarkers

›
"When Ignace Vergote opted to specialise in gynaecological oncology, his country wasn't ready, and he's been waiting for the...
Saturday, January 29, 2011

Lancet (abstract) Retraction: validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

›
Note: full details available to subscribers ($$$)  Comment Retraction—validation of gene signatures that predict the response of bre...
Saturday, January 22, 2011

short (very) commentary: EORTC 55971: Does it apply to all patients with advanced state ovarian cancer?

›
Research Highlights ► Within this randomized trial a statistical benefit was seen with primary surgery among patients with less than 5 ...
Friday, December 17, 2010

Quality of pathology reports for advanced ovarian cancer: Are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial

›

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

›
Sunday, August 08, 2010

abstract: How to follow-up patients with epithelial ovarian cancer : Current Opinion in Oncology

›
How to follow-up patients with epithelial ovarian cancer Miller, Rowan E; Rustin, Gordon JS Abstract Purpose of review: Despite optimal ...
Wednesday, May 26, 2010

abstract: How to follow-up patients with epithelial ovarian cancer.

›
Abstract PURPOSE OF REVIEW: Despite optimal primary treatment most patients with advanced epithelial ovarian cancer will relapse. This re...